20240314-华鑫证券-派林生物-000403.SZ-公司事件点评报告_与新疆德源深化战略合作_助力提升公司经营业绩_5页_229kb

报告摘要

Company: 派林生物 (Sinopharm Biological, 000403SZ)
Event: Signed a supplementary agreement with Xinjiang Deyuan on March 14, 2024. The agreement extends the cooperation period, sets new supply targets, and introduces a tiered incentive mechanism.
Investment Rating: Buy (首次 coverage)
Key Stakeholders: 胡博新, 吴景欢

Extended Cooperation Period: Agreement renewed until June 21, 2028, enhancing stability.
Increased Supply Target: Target supply quantity per year raised to 200 tons of plasma in the third cooperation year.
Tiered Incentive Mechanism: Price increases (RMB 70,000 per ton for volumes >200 tons) and rewards (RMB 500,000 for >500 tons/year, additional RMB 500,000 for >600 tons/year) to motivate increased supply.

Industry: High entry barrier (28 licensed companies in China).
Key Drivers: Plasma collection stations (浆站) and collection quantity ("采浆量") are critical for long-term development.
Company Position: Leading in China (38 stations, 11 products as of 2023H1).
Strategy: Achieved跨越式发展 (cross-stage development) through internal growth and external collaboration.

Enhanced Plasma Supply Capacity: Securing long-term, stable raw plasma supply.
Increased Collaboration Stability: Reinforced relationship between partners.
Economic Incentives: Encourages Xinjiang Deyuan to boost plasma supply through price escalation and rewards.
Positive Impact: Supports sustained cooperation, strengthens Sinopharm Biological's scale advantage and overall business performance.

High Market Demand & Barriers: Blood products remain in long-term demand. Uphold industry growth prospects.
Strong Growth Catalysts: New ownership (Sichuan SOE), planned increased number of stations, and the agreement effectively boost blood plasma production capacity.
Financial Projections (2023-2025):
- EPS: 0.82, 1.06, 1.25 RMB/share.
- PE Ratios: 34.7x, 27.1x, 22.8x.
- Revenue and profit growth rates expected remain high.
Supportive Market Performance: Recent market performance considered positive.